Melodie Young, MSN, RN, ANP-C, covers practical tips for navigating access to newer atopic dermatitis treatments through specialty pharmacies.
Topics Covered:
Accessing newer AD medications
Specialty pharmacy logistics and coordination
Navigating insurance and prior authorizations
Practical support for patients and providers
Explore Related Resources:
Dr. Blauvelt discusses the safety and efficacy of upadacitinib in patients with moderate-to-severe atopic dermatitis (AD). In terms of efficacy, he references the Heads Up
Dr. Chiesa Fuxench discusses the role of topical ruxolitinib for patients with mild-to-moderate atopic dermatitis, including those who have not responded adequately to topical corticosteroids
Andrew Mastro, MS, PA-C, outlines the proper clinical application of ruxolitinib cream 1.5% as a noncontinuous topical treatment for mild-to-moderate atopic dermatitis in nonimmunocompromised patients
Dr. Gooderham discusses using systemic Janus kinase (JAK) inhibitors like upadacitinib in patients with atopic dermatitis. She reviews appropriate indications for patient selection with JAK
David Seiter, FNP-C, shares a patient success story involving a teenage patient with severe atopic dermatitis that achieved complete skin clearance within one week after
Christopher Bunick, MD, PhD, an associate professor of dermatology at Yale School of Medicine in New Haven, Connecticut, discusses a poster presentation comparing the itch
Dr. Shahriari reviews the FDA’s decision to remove certain “black box” warnings for hormone replacement therapy (HRT) and discusses how this shift may influence treatment
Dr. Guttman-Yassky discusses a post-hoc analysis that evaluated the efficacy of upadacitinib after 140 weeks in patients with atopic dermatitis.
Dr. Lisa Swanson highlights three effective nonsteroidal topical therapies for managing atopic dermatitis in both pediatric and adult patients. Topics Covered: Nonsteroidal topical options for
